Additional indication approved for Nexium

The Korea Food and Drug Administration said it has approved additional indication of AstraZeneca’s Nexium (esomeprazole) – prevention of duodenal re-hemorrhage after endoscopic treatment (Nexium injection and maintenance therapy (Nexium tablet).

Esomeprazole is a proton pump inhibitor developed and marketed by AstraZeneca which was approved in Korea in October 2000 in the treatment of dyspep...